Pediatrics
Audio Summaries

IPNA clinical practice recommendations for the management of aHUS and secondary TMA in children

The authors aim to establish Clinical Practice Recommendations (CPRs) and Practice Points (CPPs) for the diagnosis and management of atypical hemolytic uremic syndrome (aHUS) and secondary thrombotic microangiopathies (TMAs) in children, based on expert consensus and current evidence. They formulated six structured clinical questions to guide their recommendations, resulting in 51 CPRs and 9 CPPs that address various forms of aHUS and secondary TMA, while considering the unique challenges faced in less resourced countries. Ultimately, the goal is to standardize care and improve patient outcomes globally.

Butyrylcholinesterase alleviates hepatic stellate cell activation via paracrine muscarinic signalling

The authors investigate the role of butyrylcholinesterase (BuChE) in regulating fibrosis through its effect on acetylcholine (ACh) bioavailability and downstream cholinergic signaling in hepatic stellate cells (HSCs). They find that reduced BuChE expression correlates with increased HSC activation and fibrosis, while BuChE overexpression has a protective effect. The study identifies a novel cholinergic circuit involving ChRM3 signaling that could serve as a therapeutic target for fibrosis treatment.

Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma

This phase 1 study investigates the safety and efficacy of anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR T-cell therapy, in patients with relapsed or refractory multiple myeloma who have undergone multiple prior treatments. The results indicate a high response rate (100%) with a significant proportion achieving complete response (79%), while adverse events, particularly cytokine release syndrome and neurotoxicity, were mostly mild. The findings suggest that anito-cel may be a promising treatment option for this challenging patient population.

Combined results of the TETON-1 and TETON-2 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis

The authors aimed to evaluate the efficacy of inhaled treprostinil in slowing lung function decline and improving clinical outcomes in patients with idiopathic pulmonary fibrosis (IPF) by analyzing combined results from the TETON-1 and TETON-2 trials. The study found that treprostinil significantly reduced the rate of decline in forced vital capacity and delayed clinical worsening compared to placebo, with additional benefits observed in quality of life and other secondary endpoints. These findings support the use of inhaled treprostinil as a treatment option for IPF patients.

Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome

This study investigates the efficacy and safety of etuvetidigene autotemcel (etu-cel), an autologous gene therapy, for treating Wiskott-Aldrich syndrome, a rare genetic disorder. The results indicate a high overall survival rate of 96% at both 1 and 5 years post-treatment, along with a significant reduction in severe infections and bleeding events after therapy. The findings suggest that etu-cel provides a sustained clinical benefit for patients with this condition.

Clinical Uses of Common Genetic Variants Associated with Common Diseases

The authors investigate why the integration of polygenic risk scores and genomic knowledge into clinical practice for common adult-onset diseases has been slow, despite advancements in genomics and the identification of numerous genetic variants associated with these conditions. They explore potential applications of these scores and pharmacogenomics in improving prevention and treatment strategies as genome sequencing becomes more accessible.

Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis

The authors aimed to determine whether screening with a multicancer early-detection test, in addition to usual care, reduces the incidence of late-stage cancers (stage III or IV) compared to usual care alone. In a randomized controlled trial involving over 142,000 participants, they found no significant difference in the incidence rates of stage III or IV cancers between the two groups after three screening rounds. While there was a trend towards a lower incidence of stage IV cancers, the results were not conclusive, indicating the need for further follow-up.

Biologic outcomes in severe asthma patients by smoking status: evidence from SHARP

This study investigates the efficacy of biologic treatments for severe asthma in patients with varying smoking statuses, aiming to determine whether smoking exposure affects treatment outcomes. The findings indicate that all groups, including current and ex-smokers, experienced significant improvements in asthma control and quality of life after one year of biologic therapy, challenging the prevailing reluctance to prescribe biologics to smokers. The authors advocate for further randomized controlled trials to better inform treatment guidelines for this population.

Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer

The authors aimed to evaluate the long-term efficacy of adjuvant S-1 in improving overall survival (OS) in patients with resected biliary tract cancer (BTC) compared to observation alone. The 5-year follow-up results from the ASCOT trial demonstrated that S-1 significantly improved OS (64% vs. 52%) and median OS (8.2 years vs. 5.9 years), confirming its sustained survival benefit and supporting its use as a standard treatment for resected BTC.

Autologous Platelet-Rich Plasma-Enriched Chondral Matrix Implantation Improves Cartilage Repair in an Ovine Model: A Magnetic Resonance Assessment Using the MOCART 2.0 Scoring System

The authors aimed to evaluate the effectiveness of autologous chondral platelet-rich plasma matrix implantation (PACI) in enhancing cartilage repair in an ovine model, using magnetic resonance imaging and the MOCART 2.0 scoring system. The results indicated that PACI treatment significantly improved cartilage repair compared to control treatments, demonstrating better defect filling, integration with surrounding cartilage, and overall structural quality. These findings suggest that PACI combined with plasma rich in growth factors could be a promising approach for treating focal cartilage defects in active patients.